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Summary Nasopharyngeal carcinoma (NPC) is a speciﬁc entity different from head and neck
carcinoma. Incidence is higher in South-East Asia and North Africa. Prognosis, especially for
locally advanced stages (IIB - IVB) and metastasis, remains poor: more than third of cases will
present local and/or metastatic recurrence. Overall 5-year survival for all NPC stages ranges
from 50% to 70%.
The role of chemotherapy in metastasis is well established, and remains an important pal-
liative treatment, although no randomized trial has been reported comparing the different
chemotherapy regimens. As 1st-line treatment, platin-based regimens seems optimal; in 2nd
line and after progression under platins, there is no consensus: monotherapy with drugs such
as gemcitabine, capecitabine or taxanes has been the most widely tested, with acceptable
results. Future trials should integrate targeted therapy, in the light of overexpression of EGFR1
and C-kit in NPC.
The present study presents a review of the literature concerning the various studies of
metastatic NPC.
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Introduction
Nasopharyngeal carcinoma (NPC), of epidermal origin, con-
stitutes 90% of malignant nasopharyngeal tumors. It is
classiﬁed in two clinico-histologically distinct entities: epi-
dermoid carcinoma, and undifferentiated carcinoma of
nasopharyngeal type (UCNT); the latter shows the greater
prevalence worldwide. UCNT differs from other forms of epi-
dermoid carcinoma of the upper aerodigestive tract (UADT)
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n its histologic features, and an epidemiology unrelated to
lcohol or smoking but with a direct relation to Epstein-Barr
irus (EBV). It is endemic in certain areas (highly in South-
ast Asia, and, to a slightly lesser extent, in North Africa)
1], with multifactorial etiology implicating genetic, viral
nd environmental factors.
Unlike other head and neck tumors, NPC shows a rate
s high as one-third for local or locoregional recurrence or
etastasis. [2]. The role of chemotherapy is well established
or metastasis, with a high level of objective response,
nduring remission and some cases of long survival [3].
The present study is an update of recent data regarding
he management of metastatic nasopharyngeal carcinoma.
served.
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Table 1 Results for monochemotherapy with or without pretreatment.
Author Study n Molecule OR (%) CR (%) med PFS med OS
Dugan M et al.,
1993 [12]
Ph II 108 R +M pretreated
and not
Mitoxantrone 25 n.r 4.5 months 13 months
Au E et al.,
1998 [13]
Ph II 24M non-treated Paclitaxel/3 sem 21.7 0 7.5 months 12 months
Poon D et al.,
2005 [14]
Ph II 28M pretreated Irinotecan 14 0 3.9 months 11.4 months
Foo KF et al.,
2002 [15]
Ph II 25 M pretreated
27 M non-treated
Gemcitabine 28
48
4
3.7
3.6 months
5.1 monthss
7.2 months
10.5 months
Ma BB et al.,
2002 [16]
Retro 18 R +M pretreated
and not
Gemcitabine 34 6 31% (1 year) 48% (1 year)
Zhang L et al.,
2008 [20]
Ph II 32 pretreated Gemcitabine 43.8 0 5.1 months 16 months
63% (1 year)
Chua DT et al.,
2003 [17]
Ph II 17 R +M pretreated Capecitabine 23.5 5.9 4.9 months 7.6 months
Chua D et al.,
2008 [18]
Retro 49 R +M pretreated Capecitabine 37 6 5 months 14 months
54% (1year)
Ciuleanu E
et al., 2008
[19]
Ph II 26 R +M pretreated Capecitabine 48 9 14 months 62% (1 year)
Ngeow JY
et al., 2008
Ph II 30 R +M pretreated Weekly
Docetaxel
37 0 5.3 months 12.8 months
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OR: Objective response; CR: Complete response; n: Number of p
overall survival; n.r: not recorded; Ph II: Phase II; Retro: Retrospe
ethodology
he Medline database was searched for the period 1980 to
nd 2009, using the keywords ‘‘nasopharyngeal carcinoma’’,
‘metastatic’’, ‘‘chemotherapy’’ and ‘‘targeted therapy’’.
iagnosis of metastasis
xtension assessment
reatment strategy varies depending on whether recurrence
s local or metastatic, thus requiring thorough assessment
f remote extension, comprising lung X-ray and abdominal
ltrasound scan or thoraco-abdominal CT scan, associating,
articularly in case of stage N+ and above all N3 lymph-node
nvolvement, bone scintigraphy.
Positron emission tomography (PET scan) detects
etastatic locations (lymph-node or other remote metas-
ases) with good sensitivity and may inﬂuence treatment
trategy [4], although comparative studies are needed to
alidate this promising attitude
etastasis epidemiologyemote metastasis is frequent in NPC, with very high rates
n autopsy series, varying between 38 and 87% [5];
On initial diagnosis, metastasis is found in just 5 to
% of patients [6]. These are mainly metachronous metas-
ases discovered in the course of evolution, usually within
t
c
n
pts; med PFS: Median progression-free survival; med OS: median
; M: Metastatic; R: Recurrent.
years of treatment. The overall rate of metastasis is
5—30%;[6].
The occurrence of metastasis is related to tumor size (T)
nd especially to lymph-node involvement (N), and is most
requent in T3-4 or N2-3 tumor and in patients presenting
ith the UCNT histologic type [7].
The most frequent metastasis location is the bone
70—80%), followed by viscera (liver, 30%; lung, 18%) and,
t lower rates, extra-cervical lymph-nodes (axillary, medi-
stinal, pelvic, inguinal) [8].
Prognosis depends on location: hepatic and/or medullary
nvolvement is of poor prognosis, while isolated bone metas-
asis may be associated with long survival [9].
edical management of metastatic NPC
hemotherapy
hemotherapy is the basic treatment for metastatic NPC,
ith numerous published conﬁrmations of efﬁcacy. Median
urvival, however, is short.
It is a remarkable fact that no randomized studies have
ompared palliative chemotherapy versus other palliative
are, or different chemotherapy protocols. Quality of life
as been little investigated. Studies have all been retrospec-
ive or phase II;
Studies of chemotherapy in metastatic NPC are difﬁ-
ult to compare, with small non-randomized series, and
o particular protocol can thus be demonstrated to be
referentially effective;
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Table 2 Results for bitherapy in local recurrence and/or metastasis with or without pretreatment.
Author Study n Protocol OR (%) CR (%) med PFS med OS
Wang T.L. et al., 1991 [22] Retro 25M Cisp + 5FU 76 8 n.r n.r
Au E. et al.,1994 [23] Ph II 24 R +M Cisp + 5FU 66 13 8 months 11 months
Chi KH et al., 1994 [24] Ph II 20 R 15M Cisp + 5FU/Lv 10080 15 13 n.r n.r 34 months14 months
Stein ME et al., 1996 [25] Ph II 18 R +M Cisp + Ifos 59 15 n.r n.r
[5pt] Yeo W et al., 1996 [26] Ph II 42M Carbo + 5Fu 38 17 n.r 12.1 months
Yeo W et al., 1998 [27] Ph II 27 R +M Carbo + Pac 59 11 6 months 13.9 months
Tan EH et al., 1999 [28] Ph II 32M Carbo + Pac 75 3 7 months 12 months
Ciuleanu TE et al., 2004 [29] Ph II 40M Carbo + Pac 27.5 7.5 3.5 months 11.5 months
Ngan RK et al., 2002 [30] Ph II 44 R +M Cisp +Gem 73 20 10.6 months 15 months
Ma BB et al., 2002 [16] Ph II 14 R +M Cisp +Gem 64 14 13% (1 year) 68% (1 year)
Wang J et al., 2008 [31] Retro 75 R +M Cisp +Gem 42.7 5.3 5.6 months 9 months
Ma BB et al., 2009 [32] Ph II 40 R +M Oxali +Gem 56.1 0 9 months 19.6 months
McCarthy et al., 2002 [33] Ph II 9 R +M (1st l) Cisp +Doc 22 0 8.4 months 76% (1 year)
Chua.DT et al., 2005 [34] Ph II 19M (1st l) Cisp +Doc 62.5 6.3 5.6 months 12.4
Li YH et al., 2008 [35] Ph II 48M (1st l) Cisp + Cape 62.5 6.3 7.7 months 13.3 months
Chua DT et al., 2000 [36] Ph II 18 R +M Ifos + 5FU/Lv 56 6 6.5 months 51% (1 year)
Huang HQ et al., 2002 [37] Ph II 34 R +M Ifos + Doc 67.6 14.7 6 months n.r
+ Doc
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Wang CC et al., 2006 [39] Ph II 39M (2nd—3rd l) Gem
Monochemotherapy
The chemotherapy agents most often used in monother-
apy in older reports were methotrexate, bleomycin,
5-ﬂuoro-uracile (5FU), cisplatin and carboplatin, with
response rates in the region of 15 to 31% [10]. Two
phase II trials speciﬁcally focusing on metastatic nasopha-
ryngeal cancer reported two other drugs as showing
efﬁcacy: an anthracycline (4-epidoxorubicine) and mitox-
antrone, with objective response (OR) rates of about 20%
[11,12].
More recent clinical trials tested other molecules (gemc-
itabine, capecitabine, paclitaxel, docetaxel and irinotecan)
in monotherapy in patients pretreated with cisplatin
[13—21] (Table 1); two (gemcitabine and capecitabine) have
been the focus of several reports, with interesting OR rates
in the range of 23—48% and median survival of between 7.2
and 14 months [15—20]; more recently again, the ﬁrst study
of docetaxel in monotherapy in this indication reported
comparable results [21].
Polychemotherapy
First-line polychemotherapy with platin-based doublets
[22—30,16,31—35] gave interesting response rates: OR,
50—90%; complete remission (CR), 5—30% (Table 2). These
rates were higher than obtained with isolated cisplatin. In
second line following platin resistance, associations without
platin have been tested, but not subjected to randomized
assessment [36—39].
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[33.3 0 7 months n.r
R 36 3 5.6 months 11.9 months
The association of cisplatin (100mg/m2) and 5FU in
ontinuous perfusion (1 g/m2) for 3—5 days was the most
requently tested polychemotherapy protocol in the older
tudies, giving OR between 66% and 78% and median sur-
ival up to 11 to 14 months [22—24]; by virtue of its
ctivity, low myelotoxicity and good tolerance, this asso-
iation is the standard ﬁrst-line attitude in several centers
n Asia.
In recent studies, platins (cisplatin, carboplatin or
xaliplatin) were associated with other molecules:
emcitabine, paclitaxel, docetaxel or capecitabine
27—30,16,31—35]; paclitaxel-carboplatin [27—30],
emcitabine-cisplatin [30,16,31] and docetaxel-cisplatin
33,34] were the most widely tested, giving similar results:
R 25—75% and median survival 9.5—15 months. There
as, however, been no randomized comparison against
FU-cisplatin.
Other studies tested polychemotherapy protocols associ-
ting platins and more than two other drugs, but without
nding any major impact on survival (Table 3). The
APABLE trial, for example, associated ﬁve molecules (cis-
latin, methotrexate, bleomycin, cyclophosphamide and
driamycin) and obtained a very good OR rate of 80%
ith 7% CR, but at the cost of very elevated toxicity and
high rate of iatrogenic death (11%) with no improve-
ent in overall survival (OS) [40]. Other trials reported
imilar ﬁndings: improved OR but elevated toxicity induc-
ng 11—13% mortality with no beneﬁt in terms of OS
40—47].
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Table 3 Results for polychemotherapy (> 2 molecules) in local recurrence and/or metastasis.
Author Type of
study
n Protocol OR
(%)
CR
(%)
PFS OS Toxicity
Boussen
H., et al
1991 [41]
Ph II 49
R +M
pretreated
and not
Cisp + B + 5FU 79 19 9.5%
(50
months)
n.r
Su W., et
al
1993 [42]
Ph II 25
R +M
Cisp + B + 5FU 40 3 n.r n.r Neutropenia
Gr 3/4: 36%
Toxic death:
12%
Azli N., et
al
1995 [43]
Ph II 44
R +M
pretreated
and not
BEC B + Epi + Cisp 45 20 8.9% (53
months)
n.r
Siu LL.,
et al 1998
[40]
Ph I/II 17 R
44 M
CAPABLE 41
80
23.5
6.8
n.r
n.r
16 months
14 months
Toxic death
11.5%
Taamma
A., et al
1999 [44]
Ph II 23
R +M
FBEC
5FU+B +
Epi + Cisp
78 39 13%
(42
months)
n.r Neutropenia
Gr4 51%
Mucitis
Gr3/4 30%
Toxic death:
13%
Hasbini A.,
et al 1999
[45]
Ph II 44
R +M
FMEP
5FU+M+
Epi + Cisp
52 13 9 months 14 months Neutropenia
Gr 3—4: 89%
Febrile neu-
tropenia:
36%
Mucitis Gr
3—4 32%
Toxic death
(9%)
Leong SS.,
et al 2008
[46]
Ph II 28
M
Carbo +G+Pacli +
5FU/Lv (maint)
86 11 8 months 22 months Neutropenia
Gr 3/4: 79%
Anemia
Gr3—4: 32%
Huang
HQ., et al
2008 [47]
Ph II 56
R +M
DCF
(Doc +Cisp + 5FU)
72.5 9.8 n.r n.r Neutropenia
Gr2—4:
10.5%
Febrile neu-
tropenia:
3.6%
OR: Objective response; CR: Complete response; med PFS: Median progression-free survival; med OS: median overall survival; n: Number
of patients; n.r: not recorded; M: Metastatic; R: Recurrent; Ph II: Phase II; Retro: Retrospective; Cisp: Cisplatin; 5Fu: 5-Fluorouracile; Ifos:
o: Ca
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[Ifosfamide; Pac: Paclitaxel; Doc: Docetaxel; G: Gemcitabine; Carb
VNR: Vinorelbine; Lv: Leucovorin; CAPABLE: Cyclophosphamide +
Maint: Maintenance; Gr: Grade.
The results of the published trials are to be interpreted
ith caution before considering one protocol or drug as
ore effective than another: the studies are very diver-
ent, with heterogeneous populations, including isolated
ocoregional rrecurrence or metastasis, with and without
retreatment, ﬁrst, second and third line treatments, hav-
ng already received platins or not; they were moreover
ainly retrospective studies or phase II trials and not ran-
omized.
o
p
s
arboplatin; B: Bleomycine; Cape: Capecitabine; Oxali: Oxaliplatin;
mycin +Doxorubicin + Cisplatin; DCF: Docetaxel + 5FU +Cisplatin;
hoice of ﬁrst and second line chemotherapy
n ﬁrst-line treatment of metastasis, platin-based bitherapy
s generally recommended, and 5FU cisplatin in particular
48].In second line treatment of metastasis, the choice
f chemotherapy depends on the previous treatment. In
atients pretreated with platins, there is no established
tandard, reintroduction of platins depending on toxicity
nd the interval to recurrence: for an interval greater than
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6—12 months, a second platin-based doublet associating tax-
anes or gemcitabine seems to be the most effective, with OR
22—75% but with associated grade 3—4 hematologic toxicity,
which my act as a limitation. Second line capecitabine, gem-
citabine or docetaxel monochemotherapy is recommended
in case of platin resistance (early [< 6months] recurrence)
or in fragile subjects in whom toxicity could be threatening
[48].
Targeted therapy
There are few studies of targeted treatment of metasta-
sis, but Phase II studies have been published in the light
of overexpression of EGFR1 and C-kit. Geﬁtinib was tested
in two studies; results were disappointing, with no OR but
rather stabilization: a ﬁrst phase II study on a small series
of 19 patients with local recurrence or metastasis after sec-
ond line failure of chemotherapy reported no OR, 4 months’
progression-free survival (PFS) and 16 months’ OS [49]; the
second study, which was stopped for lack of efﬁcacy, con-
cerned 15 patients, showing 20% stabilization, 2.7 months’
PFS and 12 months’ OS [50].
Another tyrosine kinase inhibitor (TKI), sorafenib, was
tested in epidermoid head and neck carcinoma and
metastatic or recurrent NPC after at least one line of
chemotherapy, but showed weaker response than found for
chemotherapy [51].
A phase II study tested a monoclonal antibody, cetux-
imab, in association with carboplatin in 59 patients
overexpressing EGFR, in local or metastatic recurrence 12
months after platin chemotherapy: again, response was
weak, often with stabilization (OR 11.7%, CR 0%, disease
stabilization 48.3%), at the cost of signiﬁcant toxicity (grade
3/4: 51.7%), median PFS being 2.8 months and OS 7.8 months
[52].
Other treatments for metastasis
Locoregional radiation therapy
In primary metastasis, locoregional radiation treatment may
be indicated after control by chemotherapy; it improves
disease control and quality of life [53].
Metastasis surgery
Pulmonary metastasis resection may be recommended for
limited pulmonary metastasis; good resultant control was
reported [54].
Role of bisphosphonates
Recent studies demonstrated speciﬁc efﬁcacy of bisphospho-
nates in bone metastases of NPC [55].Conclusion
In metastasis, chemotherapy is mandatory for patients with
a good performance status index; the 5FU-cisplatin associa-
tion is most widely used in ﬁrst-line; recent studies showed
[83
ther drugs to be effective, in monotherapy or in associa-
ion: docetaxel, paclitaxel, gemcitabine and capecitabine.
However, well-designed randomized studies will be
eeded, in order to determine treatment standards. More-
ver, targeted therapy should be included in future trials.
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